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Abstract
The regulatory function of α1B-adrenoceptors in mammalian heart homeostasis is controversial. The objective of the present 
study was to characterize the expression/activity of key proteins implicated in cardiac calcium handling (Na+/K+-ATPase and 
Ca2+-ATPases) and growth (ERK1/2, JNK1/2 and p38) in mice with cardiac-selective overexpression of constitutively active 
mutant α1B-adrenoceptor (CAMα1B-AR), which present a mild cardiac hypertrophy phenotype. Immunoblot assays showed that 
myocardial plasma membrane Ca2+-ATPase (PMCA) expression was increased by 30% in CAMα1B-AR mice (N = 6, P < 0.05), 
although there was no change in sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2) expression. Moreover, total Ca2+-ATPase 
activity was not modified, but a significant increase in the activity of the thapsigargin-resistant (PMCA) to thapsigargin-sensitive 
(SERCA) ratio was detected. Neither Na+/K+-ATPase activity nor the expression of α1 and α2 subunit isoforms was changed 
in CAMα1B-AR mouse hearts. Moreover, immunoblot assays did not provide evidence for an enhanced activation of the three 
mitogen-activated protein kinases studied in this stage of hypertrophy. Therefore, these findings indicate that chronic cardiac 
α1B-AR activation in vivo led to mild hypertrophy devoid of significant signs of adaptive modifications concerning primary intra-
cellular calcium control and growth-related proteins, suggesting a minor pathophysiological role of this adrenergic receptor in 
mouse heart at this stage of development.
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In mammalian heart, adrenoceptors (AR) mediate 
myocyte contraction and growth induced by the sympa-
thetic nervous system. The β1-AR is the most abundant 
cardiac AR subtype and its functional importance has been 
extensively studied (1). However, other AR subtypes are 
present in the heart and their relevance to pathophysi-
ological conditions has been studied in recent years (2,3). 
The α1-AR, which primarily activates Gαq protein-coupled 
phospholipase Cβ signal transduction, has been implicated 
mostly in cardiomyocyte growth in vitro (2-5). In vivo, how-
ever, unbiased myocardial responses are impossible to 
evaluate conclusively because of the vasoactive effect of 
α1-AR agonists. In addition, the restricted number of ap-
propriate subtype-selective ligands, especially for α1B-AR 
(1,2), makes the elucidation of specific effects of different 
α1-AR particularly challenging. 
In order to overcome these drawbacks, transgenic 
mouse models overexpressing distinct myocardial-targeted 
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α1-AR subtypes have been generated, i.e., either the wild-
type (WT) or the agonist-independent constitutively active 
α1-AR (6). In the case of α1B-AR, these models exhibited 
a certain degree of cardiac dysfunction/hypertrophy (7-11), 
although some studies have found clear-cut cardiac hyper-
trophy just at an advanced age (9-11). Interestingly, cardiac 
hypertrophy was also reported in systemic overexpression 
of constitutively active or WT α1B-AR, a phenomenon not 
due to pressure load since these animals presented a nor-
motensive (WT α1-AR) or even hypotensive (constitutively 
active α1-AR) phenotype (12,13). In contrast, other studies 
have not detected any sign of cardiac hypertrophy in these 
models (14-17) or have observed them only after marked 
hypertrophic stimuli (16,18), indicating that the function of 
α1B-AR in murine heart is still a debatable issue. 
P-type ATPases are membrane-bound ion-transporting 
proteins that are vital for cell function and are particularly 
involved in myocardial ion homeostasis. It is well known that 
some members, such as Na+/K+-ATPase α2 isoform and 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2), are 
down-regulated by cardiac stress associated with adrenergic 
stimulation and may progress to hypertrophy and failure 
(19,20). For cardiac plasmalemmal Ca2+-ATPase (PMCA), 
an early expression increase and further decline apparently 
reflect an initial adaptation to facilitate calcium removal 
and are the basis of more persistent cardiac dysfunction, 
respectively (21).
Stress-induced changes mediated by persistent stres-
sors may contribute to cardiac hypertrophy. In fact, an 
increasing number of intracellular signaling pathways have 
been described as important transducers of the hypertrophic 
response, such as the mitogen-activated protein kinases 
(MAPKs) (22). Recent studies indicate that α1-AR may signal 
through MAPK pathways to stimulate growth responses in 
rat but not mouse cardiomyocytes (23). More importantly, 
MAPKs are also able to cross-talk and regulate intracellular 
calcium-handling proteins (24).
Because of the controversial role of cardiac α1B-AR 
and the absence of information regarding the specific 
regulatory function of this receptor on proteins involved in 
cardiac calcium homeostasis in vivo, we used transgenic 
mice that overexpress myocardial-targeted constitutively 
active mutant α1B-AR (CAMα1B-AR mice) (7) in order to 
evaluate the activity and expression of cardiac ion transport 
ATPases (Na+/K+-ATPase, SERCA and PMCA) and MAPKs 
(extracellular signal-regulated kinases, ERK1/2; c-Jun-N-
terminal kinases, JNK1/2, and p38). 
Material and Methods
Animal model
CAMα1B-AR transgenic male adult mice (10 to 12 
weeks old; Jackson Laboratory, USA) were maintained 
and used (7). They harbored a genetic profile in which the 
mutant α1B gene was incorporated by non-homologous 
insertion through the α-myosin heavy chain (α-MHC) 
promoter coupled to the coding sequence of CAMα1B-AR. 
Non-transgenic C57BL/6J mice (WT; Jackson Laboratory) 
served as controls. All animal procedures were approved 
by the Ethics Committee of Universidade Federal de São 
Paulo, in accordance with the Principles of Laboratory 
Animal Care published by the National Institutes of Health 
(NIH Publication #86-23, revised 1996, USA). 
Tissue collection and membrane preparations
Mice were weighed and their hearts excised, dissected, 
washed internally with a 320 mM sucrose, 1 mM EDTA and 
5 mM imidazole-HCl buffer, pH 7.2, blotted on filter paper 
and weighed. Tissue samples were immediately frozen in 
liquid nitrogen and stored at -80°C until use. Subcellular 
preparations were obtained as described (25). Organs from 
both transgenic and WT mice (approximately five hearts 
per preparation) were minced and homogenized in a 320 
mM sucrose, 5 mM imidazole-HCl buffer plus 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich, USA) 
using an Ultraturrax disperser (9500 rpm for 10 s plus two 
steps of 13,500 rpm for 10 s with a 20-s interval between 
steps), followed by filtration through gauze and ultracen-
trifugation at 100,000 gav for 45 min. A crude preparation 
was chosen because it is more suitable for quantification 
and comparison of molecular entities in muscles under 
conditions of plasticity, yielding a high and reproducible 
protein recovery (26). The pellet was resuspended in the 
same buffer without PMSF and stored at -80°C. Protein 
concentration was determined by the Lowry protein assay, 
using bovine serum albumin as standard. 
[3H]-prazosin binding assay
Saturation experiments were carried out at 25°C in 1 mL 
of a buffered solution, pH 7.4, containing 1 mM EDTA, 50 mM 
Tris-HCl, 0.5 nM [3H]-prazosin (specific activity 80 Ci/mmol; 
New England Nuclear, USA) and increasing concentrations of 
unlabeled prazosin (0.1-20 nM), in parallel for both prepara-
tions (CAMα1B-AR and WT mice). This protocol, classically 
referred to as competition experiment, allows the use of lower 
amounts of radioligand and preparation (25). The reaction 
was started by adding 200 µg protein and was stopped after 
45 min by adding 4 mL ice-cold 5 mM Tris-HCl buffer, pH 
7.4, twice and then subjected to vacuum filtration through a 
glass fiber filter (Filtrak GMF 3, Germany). Filters were then 
washed twice with 8 mL of the same buffer, dried and added 
to 10 mL of the scintillation solution (toluene containing 0.1 
g/L POPOP and 4.0 g/L PPO). Radioactivity was then mea-
sured with a Tri-Carb liquid scintillation analyzer (Packard 
Instrument Co., USA). Nonspecific binding was determined 
in the presence of 1 µM unlabeled prazosin.
Na+/K+-ATPase activity
The ATPase activity assay was performed at 37°C for 
1 h and started by adding 20-40 µg protein to a medium 
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consisting of 20 mM maleate-Tris buffer, pH 7.4, 87.6 mM 
NaCl, 3 mM MgCl2, 1.2 mM ATPNa2, 10 mM NaN3, and 1 
mM EGTA in the presence of 3 mM KCl (total activity), or 
1 mM ouabain (ouabain-resistant activity; Sigma-Aldrich). 
ATPase activity was determined by measuring the release 
of inorganic phosphate (Pi) from ATP. The Na+/K+-ATPase 
activity was considered as the difference between total and 
ouabain-resistant ATPase activities (27).
Ca2+-ATPase activity
ATPase activity was assessed in a medium containing 5 
mM Na2ATP, 0.3 mM EGTA, 4 mM MgCl2, 10 mM NaN3, 5 
μM A23187 (a Ca2+ ionophore), traces of [γ32P]-ATP and 50 
mM HEPES-Tris buffer, pH 7.4, by measuring the radioactivity 
derived from the released [32P]-Pi. Ca2+-ATPase activity was 
calculated by subtracting the basal ATPase activity (measured 
in the absence of Ca2+) from the total ATPase activity (mea-
sured in the presence of 10 µM free Ca2+, with or without 3 
µM thapsigargin; Sigma-Aldrich). The thapsigargin-resistant 
Ca2+-ATPase activity (assumed to be due to PMCA pumps) 
was subtracted from the total Ca2+-ATPase activity to obtain 
the thapsigargin-sensitive Ca2+-ATPase activity (assumed 
to be due to SERCA pumps) (28).
Immunoblotting assays
Proteins were separated by 10% SDS-PAGE and 
electrotransferred to nitrocellulose membranes. Blots 
were incubated for 1 h in 5% non-fat dry milk dissolved in 
Tris-buffered saline solution containing 0.1% Tween 20. 
Subsequently, membranes were incubated for 1 h at room 
temperature with one of the following primary antibodies: 
monoclonal mouse IgG anti-Na+/K+-ATPase α1 (McK1) 
and α2 (McB2) isoforms (Dr. K. Sweadner, Harvard Medical 
School, Boston, MA, USA), anti-PMCA (clone 5F10, Sigma 
Chemical, USA), anti-SERCA2 (Calbiochem, EMD Chemi-
cals, USA) or polyclonal rabbit anti-total or phospho-MAPKs 
antibodies (ERK1/2, p38 or SAPK/JNK; Cell Signaling 
Technology, USA) and for 1 h with horseradish peroxidase-
conjugated anti-mouse (ATPases) or anti-rabbit (MAPKs) 
antibody (Promega, USA). Proteins were detected 
using an ECL detection kit (GE Healthcare Life Sci-
ences, USA) and blot images were captured with a 
Bio-Rad GS-700 Imaging Densitometer and analyzed 
using the Quantity One Imaging software (Bio-Rad 
Laboratories, USA) (25,28). Loading control was 
performed by densitometric examination of Ponceau 
red staining as well as total MAPK blotting.
Data analysis
Values from equilibrium binding experiments 
(dissociation constant, Kd, and maximal number 
of binding sites, Bmax) were calculated assuming 
the existence of one class of specific binding sites 
in the range of concentrations used, by means of 
computerized non-linear regression analysis of the 
untransformed data (Prism 4.0, GraphPad Software Inc., 
USA), as reported earlier (28). Statistical analysis for com-
paring transgenic to wild-type values was performed using 
the unpaired Student t-test (P < 0.05).
Results
Phenotype analysis of CAMα1B-AR mice
Increases in heart/body weight ratios are classically 
associated with the occurrence of myocardial hypertrophy 
(7,25). A small but significant increase of this ratio (22%) 
was observed in transgenic mice (WT = 3.95 ± 0.05 and 
CAMα1B-AR = 4.85 ± 0.08 mg/g, N = 30; P < 0.01), which 
resulted exclusively from an increase in cardiac mass (WT 
= 116.9 ± 2.7 and CAMα1B-AR = 148.0 ± 3.3 g, N = 30; 
P < 0.01), as the body weight did not change (WT = 29.5 
± 0.4 and CAMα1B-AR = 30.5 ± 0.3 g, N = 30). This mild 
hypertrophy is consistent with a previous report (7).
The quantification of α1B-AR tissue density is not pos-
sible due to the lack of a selective ligand for this subtype 
of α1-AR (2,3,7). Therefore, the global estimation of such 
receptors through binding assays with [3H]-prazosin or [3H]-
HEAT has become a consensual method (7). Data obtained 
in [3H]-prazosin binding assays showed an increase in total 
α1-AR binding (Bmax) of approximately 70% (WT = 123.7 
± 31.3 and CAMα1B-AR = 214.6 ± 32.0 fmol/mg, N = 6; P 
< 0.01), indicating a significant increase of α1-AR density 
in transgenic hearts. 
Ca2+-ATPase activity and protein expression
Maximal cardiac Ca2+-ATPase activity was similar for 
WT and CAMα1-AR mice (Table 1). On the other hand, 
the relative contribution of SERCA and PMCA to the total 
Ca2+-ATPase activity was statistically different: while in 
our preparation the contribution of the two Ca2+-ATPases 
was not different in WT mice, the thapsigargin-resistant 
PMCA contribution was significantly higher than the 
thapsigargin-sensitive SERCA contribution in transgenic 
mice (Table 1). 
Table 1. Cardiac P-type ATPase activities of wild-type and myocardial-
targeted constitutively active mutant α1B-AR (CAMα1B-AR) mice. 
Enzyme activity 
(µmol Pi·mg protein-1·h-1)
Wild-type CAMα1B-AR
Total Ca2+-ATPase 6.98 ± 2.92 5.13 ± 1.53
Thapsigargin-sensitive Ca2+-ATPase 2.88 ± 0.50 1.07 ± 0.73
Thapsigargin-resistant Ca2+-ATPase 4.10 ± 0.71 4.06 ± 0.48*
Total Na+/K+-ATPase 1.17 ± 0.17 1.30 ± 0.16
Data are reported as means ± SEM (N = 6 preparations of 5 hearts 
each). *P < 0.05 compared to CAMα1B-AR thapsigargin-sensitive Ca2+-
ATPase (unpaired Student t-test).
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Western blot assays performed to determine the ex-
pression of the SERCA2 isoform in this model showed 
bands with similar relative absorbance in both groups (WT 
= 100 ± 9 and CAMα1B-AR = 108 ± 5%, N = 3; Figure 1), 
in accordance with functional biochemical data. On the 
other hand, the amount of PMCA protein was significantly 
increased in transgenic heart preparations, i.e., about 30% 
compared to WT (WT = 100 ± 7 and CAMα1B-AR = 132 ± 
4%, N = 6; P < 0.05; Figure 1). 
Na+/K+-ATPase activity and protein expression 
Maximal Na+/K+-ATPase activity of heart preparations 
did not differ between groups (Table 1). Similarly, there was 
no significant difference between groups in the expression 
pattern of the two major cardiac α subunit isoforms of Na+/
K+-ATPase (α1: WT = 100 ± 11 and CAMα1B-AR = 113 ± 
12%, N = 6; and α2: WT = 100 ± 8 and CAMα1B-AR = 115 
± 7%, N = 6; Figure 1). 
Stress-signaling MAPK protein expression
In order to determine whether MAPK pathways are 
activated in the present model of mild heart hypertrophy, 
we performed immunoblot assays to evaluate the expres-
sion of the three main MAPKs (ERK1/2, JNK1/2 and p38) 
in their activated (phosphorylated) form. All three MAPKs 
could be detected in every heart preparation. An equivalent 
expression pattern was found for both total (data not shown) 
and phosphorylated forms of ERK1/2 (WT = 100 ± 11 and 
CAMα1B-AR = 91 ± 11%, N = 6), JNK1/2 (WT = 100 ± 13 
and CAMα1B-AR = 88 ± 9%, N = 6) and p38 (WT = 100 ± 
10 and CAMα1B-AR = 106 ± 6%, N = 6; Figure 1). 
Discussion
Due to their lower density in mammalian hearts com-
pared to the β-AR and the lack of drugs with suitable 
selectivity, the role of α1-AR subtypes in cardiac function 
is still poorly understood. The hypertrophic effect of α1-AR 
agonists on isolated rat cardiomyocytes has been known 
for a long time (4) and has been claimed to be mediated by 
the α1A-AR subtype (29). Nevertheless, results from trans-
genic mouse models indicated that α1B-AR, but not α1A-AR, 
is probably involved in the adaptive growth phenomenon 
in the heart (2,3,6). In fact, the cardiac phenotype of the 
CAMα1B-AR mice used in this study indicated a mild hyper-
trophy, in agreement with data reported by Milano et al. (7). 
Furthermore, binding data revealed a 1.7-fold increase of 
α1-AR density, similar to the 2- to 3-fold increase detected 
by others (7,16). Interestingly, different reports described the 
absence of heart hypertrophy with the same model, probably 
because of epigenetic characteristics like diet and housing 
conditions, suggesting that myocardial α1B-AR activation 
per se would be a permissive more than a causative factor 
(15,16). Considering our results (discussed below), we can 
presume that chronic cardiac α1B-AR self-stimulation alone, 
Figure 1. Protein expression of cardiac plasmalemmal (PMCA) 
and sarco/endoplasmic reticulum type 2 (SERCA2) Ca2+- 
ATPases, Na+/K+-ATPase α1 and α2 subunit isoforms and phos-
phorylated ERK1/2, JNK1/2 and p38. Representative blots of 
heart preparations from wild-type (WT) and myocardial-targeted 
constitutively active mutant α1B-AR (CAMα1B-AR) mice.
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at least at this age, is a weak inducer of pathological changes 
in the heart, as also deduced elsewhere (6,9).
The present study revealed for the first time that the 
activity and expression of important cardiac P-type ATPases 
and MAPKs were predominantly unaltered in CAMα1B-AR 
mice. SERCA2 and Na+/K+-ATPase α2 isoform down-regu-
lation has been observed in conditions of cardiac overload, 
(19,20,25), with no change of the housekeeping Na+/K+-
ATPase α1 isoform (17,25). Interestingly, cardiac-specific 
overexpression of WT α1B-AR (70- to 150-fold increase) did 
not affect SERCA2 mRNA content (9,18), as it was reported 
at the initial hypertrophic stage (30). Our results also agree 
with previous reports showing that chronic α1-AR activation 
had no effect on Na+/K+-ATPase activity in vivo (31) or pro-
tein expression in vitro (32,33). On the other hand, PMCA 
expression and PMCA-to-SERCA relative contribution to 
total Ca2+-ATPase activity increased in CAMα1B-AR mice, 
suggesting that alterations of sarcolemmal calcium transport 
might be a maladaptive mechanism during the development 
of cardiac hypertrophy (34). Interestingly, PMCA has been 
associated with myocardial growth (35) and, via neuronal 
nitric oxide synthase, exacerbates the adrenergic-induced 
hypertrophy (36), suggesting the active contribution of this 
entity to progression of the disease.
MAPK activation plays a role in the regulation of the 
hypertrophic response in vivo, although it depends on the 
pathological stage, experimental model and type of stimu-
lus (22). In comparable experimental models, activated 
MAPKs were only detected in very young but not in adult 
mice (3 and 12 weeks old, respectively) (37-39). ERK1/2 
and/or JNK1/2 stimulation has been reported in cardiac-
selective WT α1B-AR (11) and systemic CAMα1B-AR (13) 
overexpression. Nonetheless, a direct comparison with the 
present model should be considered with caution. Benoit et 
al. (11) showed a small but significant ERK1/2 activation, 
but not of the immediate upstream kinases MEK1/2, and 
their mice expressed huge amounts of α1B-AR (a 150-fold 
increase), which can lead to promiscuous receptor (trans)
activation. Chalothorn et al. (13) detected ERK1/2 and 
JNK1/2 activation, but their animals exhibited autonomic 
failure and hypotension, which may evoke compensatory 
hypertensive mechanisms. This can significantly affect 
heart α1B-AR-independent signaling. Finally, persistent 
α1B-AR activation in vivo desensitizes the MAPK response 
in vitro (40).
The present results demonstrate that long-lasting stimu-
lation of α1B-AR in murine heart provokes mild hypertrophy 
without a major influence on the expression of many proteins 
involved in cardiac homeostasis - transport ATPases (Na+/
K+-ATPase and SERCA) and MAPKs (ERK1/2, JNK1/2 and 
p38) - but an up-regulation of PMCA, which may indicate 
an initial adaptation related to an emergent hypertrophic 
process. Considering that constitutive α1B-AR activation 
persisted during the mouse lifetime, our findings might sug-
gest that α1B-AR probably has a minor pathophysiological 
function in the mouse heart.
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